BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

CureVac N.V. (NASDAQ:CVAC) is among the 13 Best German Stocks to Invest in Now. The stock has gained by over 16% in the past month, with a major surge following the June 12 announcement that the ...

Detailed price information for America's Car-Mart (CRMT-Q) from The Globe and Mail including charting and trades.

Later in the month, on June 12, BioNTech SE (NASDAQ:BNTX) announced that it would acquire CureVac for approximately $1.25 billion in shares, which is expected to further strengthen the company’s ...

On June 12, 2025, BioNTech SE (“BioNTech”) announced its entry into a definitive purchase agreement to acquire all shares of CureVac N.V. (“CureVac”), with an implied aggregate equity ...

The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to Truist Securities analysts. Meanwhile, the FDA moves forward on having ...

BioNTech SE, in collaboration with Genentech, Inc., is conducting a Phase II study titled ‘A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX ...